DE LAURENTIIS, MICHELINO
DE LAURENTIIS, MICHELINO
DIPARTIMENTO DI MEDICINA CLINICA E CHIRURGIA
Prognostic significance of necrosis, elestosis, fibrosis and inflammatory cell reaction in operable breast cancer.
1995 Carlomagno, Chiara; Perrone, F.; Lauria, R.; DE LAURENTIIS, Michelino; Gallo, C.; Morabito, A.; Pettinato, Guido; Panico, L.; Bellelli, T.; Apicella, A.; Putrella, G.; Bianco, ANGELO RAFFAELE; DE PLACIDO, Sabino
Phase I-II study of xelox and bevacizumab plus erlotinib in sequential combination (XELOX-TARAV) in first line colorectal cancer: run in part
2007 G., Tortora; Carlomagno, Chiara; Bianco, Roberto; Daniele, G; Pepe, S; Leopardo, D; Marciano, Roberta; DE LAURENTIIS, Michelino; F., Ciardiello; DE PLACIDO, Sabino
Docetaxel, vinorelbine, and zoledronic acid as first-line treatment in patients with hormone refractory prostate cancer: a phase II study.
2007 DI LORENZO, G; Autorino, R; Perdona, S; DE LAURENTIIS, Michelino; D'Armiento, FRANCESCO PAOLO; Cancello, G; Mirone, Vincenzo; Imbimbo, Ciro; Longo, Nicola; Altieri, Vincenzo; Tortora, Giampaolo; Figg, Wd; DE PLACIDO, Sabino
A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer.
2005 DE LAURENTIIS, Michelino; Arpino, Grazia; Massarelli, E; Ruggiero, A; Carlomagno, C; Ciardiello, F; Tortora, Giampaolo; D'Agostino, D; Caputo, F; Cancello, G; Montagna, E; Malorni, L; Zinno, L; Lauria, Rossella; Bianco, ANGELO RAFFAELE; DE PLACIDO, Sabino
Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study.
2004 DE PLACIDO, Sabino; Scambia, G; DI VAGNO, G; Naglieri, E; Lombardi, Av; Biamonte, R; Marinaccio, M; Carteni, G; Manzione, L; Febbraro, A; DE MATTEIS, A; Gasparini, G; Valerio, Mr; Danese, S; Perrone, F; Lauria, Rossella; DE LAURENTIIS, Michelino; Greggi, S; Gallo, C; Pignata, S.
NUCLEAR DNA CONTENT-DERIVED PARAMETERS CORRELATED WITH HETEROGENEOUS EXPRESSION PF P53 AND BCL-2 PROTEINS IN CLEAR CELL RENAL CARCINOMA
2000 Pepe, S; Ruggiero, A; D'Acquisto, M; DE LAURENTIIS, Michelino; DE PLACIDO, Sabino
Resistance to taxanes is induced by c-erbB-2 overexpression in human MCF-10A mammary epithelial cells and is blocked by combined treatment with an antisense oligonucleotide targeting protein kinase A.
2000 Ciardiello, F; Caputo, R; Pomatico, G; DE LAURENTIIS, Michelino; DE PLACIDO, Sabino; Bianco, Ar; Tortora, Giampaolo
Effect of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials
2005 Abe, O; Abe, R; Carlomagno, Chiara; DE LAURENTIIS, Michelino; DE PLACIDO, Sabino
c-erbB2 expression predicts tamoxifen efficacy in breast cancer patients.
1998 DE PLACIDO, Sabino; Carlomagno, C.; DE LAURENTIIS, Michelino; Bianco, A. R.
Targeting HER2 as a therapeutic strategy for breast cancer: a paradigmatic shift of drug development in oncology.
2005 DE LAURENTIIS, Michelino; Cancello, G; Zinno, L; Montagna, E; Malorni, L; Esposito, A; Pennacchio, R; Silvestro, L; Giuliano, Mario; Giordano, A; Caputo, F; Accurso, A; DE PLACIDO, Sabino
A Feasibilty Study of a Sequential Dose-Dense Adjuvant Regimen with Epidoxorubicin Followed by Docetaxel Followed by High-Dose Cyclophosphamide for Early Breast Cancer with 4 or More Lymph Node Metastases.
2001 Francesco, Cognetti; Arpino, Grazia; DE LAURENTIIS, Michelino; Paola, Papaldo; Chiara, Sguotti; Modesto, D'Aprile; Francesco, Recchia; DE PLACIDO, Sabino; Angelo Raffaele, Bianco
Artificial neural network analysis of circulating tumor cells in metastatic breast cancer patients.
2011 Giordano, A; Giuliano, Mario; DE LAURENTIIS, Michelino; Eleuteri, A; Iorio, F; Tagliaferri, R; Hortobagyi, Gn; Pusztai, L; DE PLACIDO, Sabino; Hess, K; Cristofanilli, M; Reuben, Jm
IS THERE A STANDARD CHEMOTHERAPEUTIC REGIMEN FOR HORMONE-REFRACTORY PROSTATE CANCER? PRESENT AND FUTURE APPROACHES IN THE MANAGEMENT OF THE DISEASE.
2003 DI LORENZO, G; Autorino, R; DE LAURENTIIS, Michelino; Bianco, Roberto; Lauria, R; Giordano, A; DE SIO, M; Darmiento, M; Bianco, Ar; DE PLACIDO, Sabino
SECOND-LINE CHEMOTHERAPY WITH A HYBRID-ALTERNATING REGIMEN OF BOLUS FLUOROURACIL MODULATED BY METHOTREXATE AND INFUSIONAL FLUOROURACIL MODULATED BY FOLINIC ACID IN PATIENTS WITH METASTATIC COLORECTAL CANCERPRETREATED WITH FLUOROURACIL. A PHASE II STUDY.
2002 Carlomagno, C; DE LAURENTIIS, Michelino; Lauria, R; Arpino, Grazia; Massarelli, E; Ferrara, C; Milano, A; VERNAGLIA LOMBARDI, A; Costanzo, R; Catalano, G; Bianco, Ar; DE PLACIDO, Sabino
Cardiovascular complications of conventional and targeted adjuvant breast cancer therapy.
2011 Harbeck, N; Ewer, Ms; DE LAURENTIIS, Michelino; Suter, Tm; Ewer, Sm
Manuale di Oncologia Clinica
1996 Bianco, ANGELO RAFFAELE; E., Biondi; Carlomagno, Chiara; Ciardiello, Fortunato; Contegiacomo, Alma; DE LAURENTIIS, Michelino; DE PLACIDO, Sabino; Lauria, Rossella; Marinelli, Alfredo; Matano, Elide; A., Morabito; Palmieri, Giovannella; Pepe, Stefano; F., Perrone; P., Tagliaferri; Tortora, Giampaolo
Targeted Therapy of Breast Cancer
2009 DE LAURENTIIS, Michelino; Zielinski, C.
HER2 as predictive marker of resistance to endocrine treatment for advanced bresat cancer: a metanalysis of published studies
2002 DE LAURENTIIS, Michelino; Arpino, Grazia; E., Massarelli; A., Ruggiero; Carlomagno, Chiara; G., Tortora; F., Ciardiello; Ar, Bianco
EXPRESSION OF EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) CORRELATES WITH DISEASE RELAPSE AND PROGRESSION TO ANDROGEN-INDEPEDENCE IN HUMAN PROSTATE CANCER.
2002 DI LORENZO, G; Tortora, G; D'Armiento, FRANCESCO PAOLO; DE ROSA, G; Staibano, Stefania; Autorino, R; D'Armiento, Maria; DE LAURENTIIS, Michelino; DE PLACIDO, Sabino; Catalano, G; Bianco, Ar; Ciardiello, F.
Mitoxantrone, etoposide and bleomycin (MEB) chemotherapy in non-Hodgkin's Lymphoma patients non-elegible for standard cyclophosphamide, doxorubicin vincristine and prednisone (CHOP) combination.
1995 P., Tagliaferri; Matano, Elide; A., Rea; M., Famiani; F., Ciardiello; G., Tortora; V., Montesarchio; A., Morabito; M., Caraglia; DE LAURENTIIS, Michelino; DE PLACIDO, Sabino; Palmieri, Giovannella; A. R., Bianco
| Titolo | Tipologia | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|---|
| Prognostic significance of necrosis, elestosis, fibrosis and inflammatory cell reaction in operable breast cancer. | 1.1 Articolo in rivista | 1995 | Carlomagno, Chiara; Perrone, F.; Lauria, R.; DE LAURENTIIS, Michelino; Gallo, C.; Morabito, A.; Pettinato, Guido; Panico, L.; Bellelli, T.; Apicella, A.; Putrella, G.; Bianco, ANGELO RAFFAELE; DE PLACIDO, Sabino | |
| Phase I-II study of xelox and bevacizumab plus erlotinib in sequential combination (XELOX-TARAV) in first line colorectal cancer: run in part | 1.5 Abstract in rivista | 2007 | G., Tortora; Carlomagno, Chiara; Bianco, Roberto; Daniele, G; Pepe, S; Leopardo, D; Marciano, Roberta; DE LAURENTIIS, Michelino; F., Ciardiello; DE PLACIDO, Sabino | |
| Docetaxel, vinorelbine, and zoledronic acid as first-line treatment in patients with hormone refractory prostate cancer: a phase II study. | 1.1 Articolo in rivista | 2007 | DI LORENZO, G; Autorino, R; Perdona, S; DE LAURENTIIS, Michelino; D'Armiento, FRANCESCO PAOLO; Cancello, G; Mirone, Vincenzo; Imbimbo, Ciro; Longo, Nicola; Altieri, Vincenzo; Tortora, Giampaolo; Figg, Wd; DE PLACIDO, Sabino | |
| A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer. | 1.1 Articolo in rivista | 2005 | DE LAURENTIIS, Michelino; Arpino, Grazia; Massarelli, E; Ruggiero, A; Carlomagno, C; Ciardiello, F; Tortora, Giampaolo; D'Agostino, D; Caputo, F; Cancello, G; Montagna, E; Malorni, L; Zinno, L; Lauria, Rossella; Bianco, ANGELO RAFFAELE; DE PLACIDO, Sabino | |
| Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study. | 1.1 Articolo in rivista | 2004 | DE PLACIDO, Sabino; Scambia, G; DI VAGNO, G; Naglieri, E; Lombardi, Av; Biamonte, R; Marinaccio, M; Carteni, G; Manzione, L; Febbraro, A; DE MATTEIS, A; Gasparini, G; Valerio, Mr; Danese, S; Perrone, F; Lauria, Rossella; DE LAURENTIIS, Michelino; Greggi, S; Gallo, C; Pignata, S. | |
| NUCLEAR DNA CONTENT-DERIVED PARAMETERS CORRELATED WITH HETEROGENEOUS EXPRESSION PF P53 AND BCL-2 PROTEINS IN CLEAR CELL RENAL CARCINOMA | 1.1 Articolo in rivista | 2000 | Pepe, S; Ruggiero, A; D'Acquisto, M; DE LAURENTIIS, Michelino; DE PLACIDO, Sabino | |
| Resistance to taxanes is induced by c-erbB-2 overexpression in human MCF-10A mammary epithelial cells and is blocked by combined treatment with an antisense oligonucleotide targeting protein kinase A. | 1.1 Articolo in rivista | 2000 | Ciardiello, F; Caputo, R; Pomatico, G; DE LAURENTIIS, Michelino; DE PLACIDO, Sabino; Bianco, Ar; Tortora, Giampaolo | |
| Effect of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials | 1.1 Articolo in rivista | 2005 | Abe, O; Abe, R; Carlomagno, Chiara; DE LAURENTIIS, Michelino; DE PLACIDO, Sabino | |
| c-erbB2 expression predicts tamoxifen efficacy in breast cancer patients. | 1.1 Articolo in rivista | 1998 | DE PLACIDO, Sabino; Carlomagno, C.; DE LAURENTIIS, Michelino; Bianco, A. R. | |
| Targeting HER2 as a therapeutic strategy for breast cancer: a paradigmatic shift of drug development in oncology. | 1.1 Articolo in rivista | 2005 | DE LAURENTIIS, Michelino; Cancello, G; Zinno, L; Montagna, E; Malorni, L; Esposito, A; Pennacchio, R; Silvestro, L; Giuliano, Mario; Giordano, A; Caputo, F; Accurso, A; DE PLACIDO, Sabino | |
| A Feasibilty Study of a Sequential Dose-Dense Adjuvant Regimen with Epidoxorubicin Followed by Docetaxel Followed by High-Dose Cyclophosphamide for Early Breast Cancer with 4 or More Lymph Node Metastases. | 4.1 Articoli in Atti di convegno | 2001 | Francesco, Cognetti; Arpino, Grazia; DE LAURENTIIS, Michelino; Paola, Papaldo; Chiara, Sguotti; Modesto, D'Aprile; Francesco, Recchia; DE PLACIDO, Sabino; Angelo Raffaele, Bianco | |
| Artificial neural network analysis of circulating tumor cells in metastatic breast cancer patients. | 1.1 Articolo in rivista | 2011 | Giordano, A; Giuliano, Mario; DE LAURENTIIS, Michelino; Eleuteri, A; Iorio, F; Tagliaferri, R; Hortobagyi, Gn; Pusztai, L; DE PLACIDO, Sabino; Hess, K; Cristofanilli, M; Reuben, Jm | |
| IS THERE A STANDARD CHEMOTHERAPEUTIC REGIMEN FOR HORMONE-REFRACTORY PROSTATE CANCER? PRESENT AND FUTURE APPROACHES IN THE MANAGEMENT OF THE DISEASE. | 2.1 Contributo in volume (Capitolo o Saggio) | 2003 | DI LORENZO, G; Autorino, R; DE LAURENTIIS, Michelino; Bianco, Roberto; Lauria, R; Giordano, A; DE SIO, M; Darmiento, M; Bianco, Ar; DE PLACIDO, Sabino | |
| SECOND-LINE CHEMOTHERAPY WITH A HYBRID-ALTERNATING REGIMEN OF BOLUS FLUOROURACIL MODULATED BY METHOTREXATE AND INFUSIONAL FLUOROURACIL MODULATED BY FOLINIC ACID IN PATIENTS WITH METASTATIC COLORECTAL CANCERPRETREATED WITH FLUOROURACIL. A PHASE II STUDY. | 2.1 Contributo in volume (Capitolo o Saggio) | 2002 | Carlomagno, C; DE LAURENTIIS, Michelino; Lauria, R; Arpino, Grazia; Massarelli, E; Ferrara, C; Milano, A; VERNAGLIA LOMBARDI, A; Costanzo, R; Catalano, G; Bianco, Ar; DE PLACIDO, Sabino | |
| Cardiovascular complications of conventional and targeted adjuvant breast cancer therapy. | 1.1 Articolo in rivista | 2011 | Harbeck, N; Ewer, Ms; DE LAURENTIIS, Michelino; Suter, Tm; Ewer, Sm | |
| Manuale di Oncologia Clinica | 2.1 Contributo in volume (Capitolo o Saggio) | 1996 | Bianco, ANGELO RAFFAELE; E., Biondi; Carlomagno, Chiara; Ciardiello, Fortunato; Contegiacomo, Alma; DE LAURENTIIS, Michelino; DE PLACIDO, Sabino; Lauria, Rossella; Marinelli, Alfredo; Matano, Elide; A., Morabito; Palmieri, Giovannella; Pepe, Stefano; F., Perrone; P., Tagliaferri; Tortora, Giampaolo | |
| Targeted Therapy of Breast Cancer | 8.01 Chairman di Sessioni di Convegni Internazionali | 2009 | DE LAURENTIIS, Michelino; Zielinski, C. | |
| HER2 as predictive marker of resistance to endocrine treatment for advanced bresat cancer: a metanalysis of published studies | 1.5 Abstract in rivista | 2002 | DE LAURENTIIS, Michelino; Arpino, Grazia; E., Massarelli; A., Ruggiero; Carlomagno, Chiara; G., Tortora; F., Ciardiello; Ar, Bianco | |
| EXPRESSION OF EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) CORRELATES WITH DISEASE RELAPSE AND PROGRESSION TO ANDROGEN-INDEPEDENCE IN HUMAN PROSTATE CANCER. | 1.1 Articolo in rivista | 2002 | DI LORENZO, G; Tortora, G; D'Armiento, FRANCESCO PAOLO; DE ROSA, G; Staibano, Stefania; Autorino, R; D'Armiento, Maria; DE LAURENTIIS, Michelino; DE PLACIDO, Sabino; Catalano, G; Bianco, Ar; Ciardiello, F. | |
| Mitoxantrone, etoposide and bleomycin (MEB) chemotherapy in non-Hodgkin's Lymphoma patients non-elegible for standard cyclophosphamide, doxorubicin vincristine and prednisone (CHOP) combination. | 1.1 Articolo in rivista | 1995 | P., Tagliaferri; Matano, Elide; A., Rea; M., Famiani; F., Ciardiello; G., Tortora; V., Montesarchio; A., Morabito; M., Caraglia; DE LAURENTIIS, Michelino; DE PLACIDO, Sabino; Palmieri, Giovannella; A. R., Bianco |